SL Science Holding SLBT

SL Science Holding Limited is a holding company with no substantive business operations of its own, conducting its activities through its subsidiary SL Bio. The company is a biomedical company specialized in developing innovative cellular and gene therapies. It focuses on advancing regenerative medicine and cancer treatment using immune stem cells and bovine-derived milk exosomes to target cancer and regenerate damaged tissues. SL Science utilizes proprietary technologies such as Armed-T and Gamma Delta T cells, along with exosome applications in skincare and cancer recovery, aiming to create cellular therapies with potential to revolutionize the cell therapy and immuno-oncology sector. Its business model centers on developing partnerships with biopharmaceutical companies to transform technologies into commercially viable drugs and cancer treatments, leveraging proprietary cell expansion platforms, strategic licensing, and academic collaborations.

SL Science generates revenue through the development and potential commercialization of its therapeutic product candidates, including CD-19 Armed-T therapy for blood cancers and Gamma Delta T cell therapies for pancreatic and brain cancer. The company also derives revenue from its legacy exosome cosmetic and plant supplement businesses, which include milk-derived exosome skincare formulations and tangerine extract-based hair care products sold in Taiwan. These legacy businesses continue to contribute to overall operations while the company phases them out as its cell therapies mature. Revenue is expected to increase upon successful clinical development, regulatory approvals, and strategic partnerships with pharmaceutical companies for large-scale trials and market access.

The company operates through the following segments: Armed-T Therapy, Gamma Delta T Cell Therapy, Exosome Cosmetics, and Plant Extract Hair Care.

• Armed-T Therapy: This segment focuses on developing bispecific antibody-armed T cell therapies, particularly CD-19 Armed-T, targeting blood cancers such as leukemia and lymphoma. The technology conjugates bispecific antibodies to immune cells to enhance anti-cancer cytotoxicity without genetic modification. SL Science has licensed this technology from CytoArm Co., Ltd and is conducting preclinical validation, including in-vitro cytotoxicity assays and manufacturing scale-up, with plans to file an IND with the FDA in Q1 2027.
• Gamma Delta T Cell Therapy: This segment develops allogeneic, off-the-shelf GDT cell therapies for pancreatic and brain cancer treatment, leveraging proprietary expansion and activation processes from peripheral blood mononuclear cells. The technology is licensed from JY BioMed and includes engineered GDT cells armed with bispecific antibodies for tumor targeting. SL Bio has completed preclinical studies showing cytotoxicity against cancer cell lines and tumor volume reduction in xenograft models, with IND submission projected for Q3 2027.
• Exosome Cosmetics: This segment involves the development and sale of milk-derived exosome-based skincare products in Taiwan, launched commercially in 2023. The products are ISO-certified, dermatologically tested, and formulated for anti-aging, skin renewal, and post-treatment recovery. SL Science sources bovine milk-derived exosomes through YC Biotech CO., LTD and markets them as non-medical cosmetics under Taiwan’s Cosmetic Hygiene and Safety Act, with no current intent to market in the U. S. as drugs.
• Plant Extract Hair Care: This segment offers tangerine extract-based hair care products formulated to promote scalp health, reduce dandruff, and enhance follicle resilience, and improve hydration. The products are ISO-certified, dermatologically tested, and manufactured under strict quality control in Taiwan using high-purity tangerine extract from certified citrus harvests. SL Science launched these products commercially in 2023 as a natural alternative to synthetic scalp treatments, with no current plans for U. S. market entry as drugs.

SL Science positions itself as an emerging player in the next-generation allogeneic cell therapy industry, particularly in GDT cell-based oncology treatments and engineered immune effector platforms. The company faces competition from platform-stage rivals such as Adicet Bio, IN8bio, GammaDelta Therapeutics (a Takeda company), and TC BioPharm in the GDT cell therapy space, and from commercial-stage CAR-T leaders like Novartis (Kymriah) and Gilead (Yescarta) in blood cancer therapeutics. Its competitive advantages include proprietary non-genetic modification approaches using bispecific antibodies, off-the-shelf GDT cell scalability, lower graft-versus-host disease risk, and strategic partnerships with CytoArm and JY Med for technology development and clinical execution.

SL Science serves patients with blood cancers, pancreatic cancer, and brain cancer through its therapeutic development programs, targeting individuals with leukemia, lymphoma, pancreatic carcinoma, and glioblastoma. The company also serves consumers in Taiwan through its exosome skincare and plant extract hair care products, sold via retail channels and corporate distribution agreements, including one with Yu Ru Health Management Consulting Co., Ltd. for pan-Asian marketing and promotional support.